Gastroenterology
<ѻý class='mpt-top_cat_title_description'>News, opinions and meeting coverage in gastroenterology.ѻý>
<ѻý>Heart Risk Prompts FDA to Pull IBS Agent Tegaserod (Zelnorm)ѻý>
ROCKVILLE, Md. -- The FDA said today that Novartis has halted sales of tegaserod (Zelnorm), its agent for irritable bowel syndrome and constipation, following suggestions of a small increase in ischemic events, including angina and stroke, in those taking the drug.
Mar 30, 2007
<ѻý>DDW: Constipation Drug Seen Safe and Effective for Long Term Use in Elderlyѻý>
Los Angeles — The new medication Amitiza (lubiprostone) is safe and effective as long-term therapy for chronic constipation in older patients, researchers reported here. Results were at least as good in seniors as in the more general populations studied earlier.
May 23, 2006
<ѻý>ACP: Causes of Constipation and Tips for Office Evaluationѻý>
PHILADELPHIA - Patients frequently complain of constipation to their physicians, but they and the doctors may be speaking at cross purposes. In a survey of patients and specialist and resident physicians, 50% of the time patient responses disagreed with physicians' answers about what is constipation.
Apr 10, 2006
<ѻý>Some NSAIDS Safe in Ulcerative Colitis or Crohn's -- Sometimes ѻý>
ROCHESTER, Minn. - Patients with quiescent ulcerative colitis or Crohn's disease can use some non-steroidal anti-inflammatory drugs safely, particularly selective cyclooxygenase inhibitors, at least some of the time, according to two studies.
Feb 03, 2006
<ѻý>Cleansing the Bowel for Colonoscopy May Harm the Kidneys ѻý>
NEW YORK - Oral sodium phosphate solutions are great at cleaning out the bowel prior to colonoscopy, but in some patients these powerful purgatives can also do a serious number on the kidneys, caution Columbia researchers.
Oct 18, 2005
<ѻý>IBD Patients Prone to Other Autoimmune or Inflammatory Disordersѻý>
PHILADELPHIA-Patients with the inflammatory bowel disorders ulcerative colitis and Crohn's disease are significantly more likely to suffer from other conditions with an inflammatory or autoimmune basis, said researchers in two separate studies.
Sep 01, 2005
<ѻý>For How Long is the Hepatitis B Vaccine Effective?ѻý>
A study of native Alaskans published in the Annals of Internal Medicine determined that vaccine-conferred immunity to hepatitis B virus persists on average about fifteen years after vaccination. The study has implications for determining effectiveness and duration of vaccine protection and possible need for booster shots.
Mar 01, 2005